CoChat
Sign Up
Cited by 278Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.

The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer’s Disease

Open access
Fernandez, Celia G., Hamby, Mary E., McReynolds, Morgan L., Ray, William J.·2019·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2019.00014PMC PMC6378415
Open this paper in CoChat — free accountOpen PDF

Abstract

APOE4 is the greatest genetic risk factor for late-onset Alzheimer's disease (AD), increasing the risk of developing the disease by 3-fold in the 14% of the population that are carriers. Despite 25 years of research, the exact mechanisms underlying how APOE4 contributes to AD pathogenesis remain incompletely defined. APOE in the brain is primarily expressed by astrocytes and microglia, cell types that are now widely appreciated to play key roles in the pathogenesis of AD; thus, a picture is emerging wherein APOE4 disrupts normal glial cell biology, intersecting with changes that occur during normal aging to ultimately cause neurodegeneration and cognitive dysfunction. This review article will summarize how APOE4 alters specific pathways in astrocytes and microglia in the context of AD and the aging brain. APOE itself, as a secreted lipoprotein without enzymatic activity, may prove challenging to directly target therapeutically in the classical sense. Therefore, a deeper understanding of the underlying pathways responsible for APOE4 toxicity is needed so that more tractable pathways and drug targets can be identified to reduce APOE4-mediated disease risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2019.00014

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The structure of APOE isoforms. APOE is a soluble secreted protein, with N-terminal and C-terminal domains linked by a central hinge region. The N-terminal domain contains the receptor binding domain (indicated in green), and the C-terminal domain contains the lipid binding region (indicated in orange). Each isoform differs from one another at amino acid position 112 and 158. Cysteine at position 158 (C158) in APOE2 is thought to cause deficient receptor binding, while arginine at position 112 (R112) in APOE4 changes the conformation of the entire domain such that R61 is exposed and interacts with C255 in the C-terminal domain (red dotted line). This “domain interaction” is thought to be the biophysical basis for differences in APOE4 function compared to the other isoforms; e.g., preference for VLDL over HDL. In APOE3 and APOE2, which have C112 instead of R112, the R61 is not exposed and there is no such domain interaction.
Figure 1 The structure of APOE isoforms. APOE is a soluble secreted protein, with N-terminal and C-terminal domains linked by a central hinge region. The N-terminal domain contains the receptor binding domain (indicated in green), and the C-terminal domain contains the lipid binding region (indicated in orange). Each isoform differs from one another at amino acid position 112 and 158. Cysteine at position 158 (C158) in APOE2 is thought to cause deficient receptor binding, while arginine at position 112 (R112) in APOE4 changes the conformation of the entire domain such that R61 is exposed and interacts with C255 in the C-terminal domain (red dotted line). This “domain interaction” is thought to be the biophysical basis for differences in APOE4 function compared to the other isoforms; e.g., preference for VLDL over HDL. In APOE3 and APOE2, which have C112 instead of R112, the R61 is not exposed and there is no such domain interaction.CC BY · PubMed Central
Figure 2 Impaired lipid transport capacity of astrocytic APOE4 sensitizes neurons to degeneration during aging. Astrocytes (red) expressing APOE3 supply normal levels of cholesterol and other lipids to the cells of the brain, particularly to neurons (yellow), maintaining healthy neuronal function and cognition. Astrocytes expressing APOE4 are less inefficient at lipid transport, which, compounded with aging-associated lipid dysregulation, leads to neurodegeneration (neuron with rough edges) and is expected to predispose APOE4 carriers to Alzheimer’s disease (AD).
Figure 2 Impaired lipid transport capacity of astrocytic APOE4 sensitizes neurons to degeneration during aging. Astrocytes (red) expressing APOE3 supply normal levels of cholesterol and other lipids to the cells of the brain, particularly to neurons (yellow), maintaining healthy neuronal function and cognition. Astrocytes expressing APOE4 are less inefficient at lipid transport, which, compounded with aging-associated lipid dysregulation, leads to neurodegeneration (neuron with rough edges) and is expected to predispose APOE4 carriers to Alzheimer’s disease (AD).CC BY · PubMed Central
Figure 3 The neuroprotective transfer of toxic lipids from neurons to astrocytes results in lipid droplet formation, which is abrogated in APOE4-expressing cells. Agents or stressors that induce reactive oxygen species (ROS) formation in neurons leads to increased levels of toxic peroxidated lipids. Neurons transfer these lipids to astrocytes via APOE. With APOE3 expression, this transfer results in the formation of lipid droplets (LDs; yellow dots) in astrocytes and neuroprotection. Conversely, APOE4 expression is thought to prevent the transfer of peroxidated lipids to astrocytes, resulting in no LD formation in astrocytes and subsequent neurodegeneration.
Figure 3 The neuroprotective transfer of toxic lipids from neurons to astrocytes results in lipid droplet formation, which is abrogated in APOE4-expressing cells. Agents or stressors that induce reactive oxygen species (ROS) formation in neurons leads to increased levels of toxic peroxidated lipids. Neurons transfer these lipids to astrocytes via APOE. With APOE3 expression, this transfer results in the formation of lipid droplets (LDs; yellow dots) in astrocytes and neuroprotection. Conversely, APOE4 expression is thought to prevent the transfer of peroxidated lipids to astrocytes, resulting in no LD formation in astrocytes and subsequent neurodegeneration.CC BY · PubMed Central
Figure 4 Different modes of glucose metabolism are preferred in the young vs. aging brain. In the young brain, aerobic glycolysis is generally favored, resulting in increased lactate production, presumably by astrocytes, which should be supportive for increased neuronal activity. With aging, there is a shift toward oxidative phosphorylation (OxPhos) instead, resulting in increased electron transport chain (ETC) activity, increased ROS production, and more peroxidated lipids. Healthy cultured cells that are resistant to Aβ toxicity happen to exhibit a preference for aerobic glycolysis, and aerobic exercise, which is known to confer neuroprotection, elevates aerobic glycolysis. In contrast, cells from familial AD patients (PSEN1ΔE9) exhibit elevated OxPhos. While young APOE4 carriers may exhibit increased glycolytic activity, particularly in brain regions associated with AD [e.g., default mode network (DMN), entorhinal cortex], aged APOE4 carriers may exhibit elevated OxPhos instead, although more evidence to demonstrate whether and how such a metabolic shift occurs is warranted.
Figure 4 Different modes of glucose metabolism are preferred in the young vs. aging brain. In the young brain, aerobic glycolysis is generally favored, resulting in increased lactate production, presumably by astrocytes, which should be supportive for increased neuronal activity. With aging, there is a shift toward oxidative phosphorylation (OxPhos) instead, resulting in increased electron transport chain (ETC) activity, increased ROS production, and more peroxidated lipids. Healthy cultured cells that are resistant to Aβ toxicity happen to exhibit a preference for aerobic glycolysis, and aerobic exercise, which is known to confer neuroprotection, elevates aerobic glycolysis. In contrast, cells from familial AD patients (PSEN1ΔE9) exhibit elevated OxPhos. While young APOE4 carriers may exhibit increased glycolytic activity, particularly in brain regions associated with AD [e.g., default mode network (DMN), entorhinal cortex], aged APOE4 carriers may exhibit elevated OxPhos instead, although more evidence to demonstrate whether and how such a metabolic shift occurs is warranted.CC BY · PubMed Central
Figure 5 The effect of APOE4 expression on microglia is cell autonomous and triggers a DAM, pro-inflammatory phenotype with impaired homeostatic functions. Microglia expressing APOE4 vs. APOE3 tend to exhibit a disease-associated microglia (DAM)-like phenotype; this includes increased pro-inflammatory cytokine production with impaired phagocytic ability, deficient clearance of debris (including amyloid plaques), and impaired migratory ability. These changes, compounded with the pro-inflammatory phenotype associated with normal aging, result in an increased risk of developing AD.
Figure 5 The effect of APOE4 expression on microglia is cell autonomous and triggers a DAM, pro-inflammatory phenotype with impaired homeostatic functions. Microglia expressing APOE4 vs. APOE3 tend to exhibit a disease-associated microglia (DAM)-like phenotype; this includes increased pro-inflammatory cytokine production with impaired phagocytic ability, deficient clearance of debris (including amyloid plaques), and impaired migratory ability. These changes, compounded with the pro-inflammatory phenotype associated with normal aging, result in an increased risk of developing AD.CC BY · PubMed Central
Figure 6 APOE4 disrupts homeostatic pathways in astrocytes and microglia to cause neurodegeneration and AD. APOE4 expression and the normal aging process itself impair astrocyte and microglia physiology in specific pathways, which could theoretically be targeted to treat AD. In addition to deficient clearance of Aβ, emerging evidence specifically highlights lipid dysregulation and deficient glucose metabolism in astrocytes, and a neurodegenerative pro-inflammatory response in microglia, and to some extent in astrocytes as well. All of these pathways converge with similar deficits that occur in normal aging to ultimately lead to neurodegeneration.
Figure 6 APOE4 disrupts homeostatic pathways in astrocytes and microglia to cause neurodegeneration and AD. APOE4 expression and the normal aging process itself impair astrocyte and microglia physiology in specific pathways, which could theoretically be targeted to treat AD. In addition to deficient clearance of Aβ, emerging evidence specifically highlights lipid dysregulation and deficient glucose metabolism in astrocytes, and a neurodegenerative pro-inflammatory response in microglia, and to some extent in astrocytes as well. All of these pathways converge with similar deficits that occur in normal aging to ultimately lead to neurodegeneration.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 278

Related

See all

Metadata

Authors
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Fernandez, Celia G.
ORCID
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2019-02-11
Volume
11
Pages
14-14
ISSN
1663-4365 (ISSN-L)
DOI
10.3389/fnagi.2019.00014
PMC
PMC6378415
OpenAlex
W2911484089
Cited by
277
References
194
Citations by year
2026: 25 · 2025: 32 · 2024: 31 · 2023: 54 · 2022: 50 · 2021: 36 · 2020: 43 · 2019: 6
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Robert A. and Renee E. Belfer Family Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
APOE ε4, Alzheimer's disease, astrocytes, microglia, brain aging, neurodegeneration, cognitive impairment, therapeutic target, genetic risk factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review